Jointly steering CMS’ life sciences practice, Ellen Gielen and Gertie Lintjens head a team engaged in a wide range of regulatory, commercial and contentious matters. Gielen advises on pharmaceutical and medical device regulation, including compliance, market-access pathways and reimbursement issues, while Lintjens focuses on R&D projects, early-access schemes and product-development questions. The practice is supported by Judith Kok, who regularly handles licensing mandates, distribution arrangements and product-specific regulatory issues.
Legal 500 Editorial commentary
Key clients
- Amgen
- Boston Scientific
- Brocacef (a company of Phoenix group)
- Carl Zeiss
- Eli Lilly
- Essity
- Fagron
- Incyte
- Johnson & Johnson
- LEO Pharma
- Mölnlycke Health Care
- Netherlands Cancer Institute (Antoni van Leeuwenhoek)
Work highlights
Litigated on behalf of Leo Pharma on a landmark appeal regarding the jurisdiction of the Dutch self-regulatory court for pharmaceutical advertising.
Advised a Dutch biotech on the impact and possible measures regarding the US most favored nation executive order on pharmaceutical pricing.
Advised El Lilly on various aspects regarding the launch of its blockbuster GIP/GLP-1 product Mounjaro in the Netherlands.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Ellen Gielen, Gertie Lintjens
Other key lawyers
Judith Kok; Renate Bik; Murat Duman